Open-Label, Randomized, 2-Way Crossover Study To Estimate The Pharmacokinetics And Bioavailability Of Lersivirine (UK 453,061) Administered As A Single 750 Mg Tablet And 3 X 250 Mg Tablets In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2010
At a glance
- Drugs Lersivirine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 10 Mar 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2010 New trial record